Oxford Biomedica (LON:OXB – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (41.75) (($0.54)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%.
Oxford Biomedica Stock Down 1.8 %
OXB stock opened at GBX 273.50 ($3.55) on Friday. Oxford Biomedica has a 1-year low of GBX 187.83 ($2.44) and a 1-year high of GBX 455 ($5.91). The stock has a market cap of £290.73 million, a price-to-earnings ratio of -2.03 and a beta of 1.09. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The company’s 50 day moving average is GBX 319.38 and its 200 day moving average is GBX 379.08.
Oxford Biomedica Company Profile
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Featured Stories
- Five stocks we like better than Oxford Biomedica
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Energy Stock Winners Even as Oil Prices Plunge
- What is a Low P/E Ratio and What Does it Tell Investors?
- Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves
- ETF Screener: Uses and Step-by-Step Guide
- Apple: Losing Its Darling Status or a Dip Buying Opportunity?
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
